Sex-Related Differences in Drug-Induced QT Prolongation: Mechanisms, Clinical Implications, and Management

Abstract

Drug-induced QT prolongation is a clinically significant adverse effect associated with an elevated risk of torsades de pointes (TdP) and sudden cardiac death. Notably, sex-related differences play a pivotal role in the susceptibility, mechanisms, and clinical outcomes of this phenomenon. Recent evidence highlights that women are disproportionately affected, with underlying pathophysiological, hormonal, and genetic factors contributing to this disparity. This comprehensive review synthesizes current epidemiological data, pathophysiological insights, risk stratification strategies, and guideline-driven approaches to the management of drug-induced QT prolongation, emphasizing sex-based differences. The article also explores recent advances, emerging therapies, and practical clinical implications for healthcare providers to optimize patient safety and outcomes in the context of QT-prolonging pharmacotherapy.

Introduction

Drug-induced QT prolongation is a well-recognized adverse drug reaction with significant clinical ramifications, most notably the predisposition to ventricular arrhythmias such as TdP. The QT interval, representing the duration of ventricular depolarization and repolarization, is sensitive to various pharmacologic agents, many of which are commonly prescribed. Sex differences in cardiac electrophysiology are increasingly acknowledged as critical determinants of arrhythmic risk, yet are often underappreciated in routine clinical practice. This review aims to elucidate the multifactorial sex-related differences in drug-induced QT prolongation, integrating recent findings and guideline recommendations to inform evidence-based management.

Epidemiology / Disease Burden

Population-based studies consistently demonstrate a higher incidence of drug-induced QT prolongation and TdP in women compared to men. The prevalence of QT-prolonging drug prescriptions is substantial, particularly among populations with polypharmacy, cardiovascular disease, or psychiatric conditions. Women exhibit a two- to three-fold increased risk of developing TdP when exposed to QT-prolonging medications. The clinical burden is further compounded by the underrepresentation of women in clinical trials and the lack of sex-specific dosing guidelines, leading to potentially preventable adverse outcomes.

Pathophysiology

The pathophysiological basis for sex-related differences in drug-induced QT prolongation is multifaceted. Women inherently possess a longer baseline QT interval, attributed to hormonal influences particularly estrogen, which modulates cardiac ion channel expression and function. Estrogen downregulates the rapid component of the delayed rectifier potassium current (IKr), mediated by the human ether-à-go-go-related gene (hERG) channel, rendering female cardiomyocytes more susceptible to drug-induced repolarization delays. Additionally, genetic polymorphisms affecting ion channel subunits, sex-specific expression patterns, and differences in myocardial repolarization reserve contribute to heightened vulnerability in women.

Risk Factors

Sex is a major non-modifiable risk factor for drug-induced QT prolongation. Other risk factors include advanced age, underlying structural heart disease, electrolyte disturbances (particularly hypokalemia and hypomagnesemia), bradycardia, renal or hepatic impairment, and high drug plasma concentrations. Polypharmacy, especially involving multiple QT-prolonging agents or metabolic inhibitors, further amplifies risk. Notably, female sex interacts synergistically with these factors, potentiating arrhythmogenic risk even at lower drug exposures.

Clinical Features

Clinically, drug-induced QT prolongation is often asymptomatic until progression to malignant ventricular arrhythmias. TdP typically presents as syncope, palpitations, or sudden cardiac arrest. Sex-related differences extend to clinical presentation, with women experiencing a higher incidence of symptomatic arrhythmic events and a greater propensity for drug-induced TdP despite similar drug exposures. Awareness of subtle prodromal symptoms and ECG changes is critical for timely intervention.

Diagnosis

Diagnosis hinges on serial ECG monitoring, with particular attention to corrected QT interval (QTc) values. The threshold for clinically significant QT prolongation is generally accepted as QTc > 450 ms in men and > 470 ms in women. Automated ECG algorithms may over- or underestimate QTc, necessitating manual confirmation, especially in patients at risk. Sex-specific reference ranges and individualized risk stratification are essential for accurate diagnosis and prevention of adverse outcomes.

Treatment & Management

Management strategies include immediate withdrawal of offending medications, prompt correction of electrolyte imbalances, and avoidance of QT-prolonging polypharmacy. In emergent cases of TdP, intravenous magnesium sulfate and temporary pacing to increase heart rate are first-line interventions. For high-risk individuals, especially women with additional risk factors, careful drug selection, dose adjustments, and close ECG surveillance are paramount. Multidisciplinary collaboration among cardiologists, pharmacists, and primary care providers enhances patient safety.

Recent Advances / Emerging Therapies

Emerging research has yielded novel risk prediction models that incorporate sex as a key variable, enhancing personalized medicine approaches. Advances in pharmacogenomics, including identification of sex-specific ion channel gene variants, offer promise for preemptive risk stratification. Innovative drug development strategies focus on minimizing hERG channel blockade and leveraging sex-specific pharmacokinetic data to inform dosing regimens. Ongoing clinical trials are evaluating the efficacy of selective hormone modulation to mitigate QT prolongation risk in women.

Guideline Recommendations

Major professional society guidelines, including those from the American Heart Association and European Society of Cardiology, emphasize the necessity of sex-specific risk assessment and management strategies. Recommendations include baseline and follow-up ECGs for all patients initiating QT-prolonging drugs, with heightened vigilance for women. Dose modifications, rigorous electrolyte monitoring, and avoidance of unnecessary polypharmacy are strongly advised. Inclusion of women in clinical trials and post-marketing surveillance is advocated to generate robust sex-specific safety data.

Conclusion

Sex-related differences in drug-induced QT prolongation represent a critical, yet frequently underrecognized, dimension of pharmacovigilance and clinical care. Women are at greater risk for adverse outcomes due to intrinsic, hormonal, and genetic factors. Clinicians must integrate sex-specific risk stratification, evidence-based monitoring, and guideline-driven interventions to minimize the incidence and impact of drug-induced arrhythmias. Continued research and education are imperative to advance precision medicine and improve patient safety in this evolving field.